{"ticker": {"uuid": "b0ba316e-94ba-485c-9a85-ed01f3f5223c", "symbol": "BNTC", "name": "Benitec Biopharma Ltd ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "(BNTC) and the Role of Price-Sensitive Allocations", "summary": "This article provides an AI-generated analysis of Benitec Biopharma Inc. (NASDAQ: BNTC), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details specific institutional trading strategies including position, momentum breakout, and risk hedging, alo", "url": "https://news.stocktradersdaily.com/news_release/101/BNTC_and_the_Role_of_Price-Sensitive_Allocations_071126093002_1783819802.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T21:39:45", "published_display": "11 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Benitec Biopharma Inc. \u2013 NASDAQ:BNTC", "summary": "This article provides financial data for Benitec Biopharma Inc. (NASDAQ: BNTC), specifically focusing on its price-to-sales forward metric. The content appears to be a stub or a section from a larger financial data platform like TradingView, showing the header for this specific m", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T04:09:52", "published_display": "03 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNTC - Benitec Biopharma Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Benitec Biopharma Inc (BNTC) as of July 2, with detailed financial metrics, performance indicators, and company statistics. It includes data points such as market capitalization, income, sales, EPS, various ratios, insi", "url": "https://finviz.com/stock?t=BNTC&ta=1&p=d&ty=lf", "source_name": "Finviz", "published_at": "2026-07-02T23:39:40", "published_display": "02 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Benitec Biopharma Ltd ADR For: 30 June By Investing.com", "summary": "This article announces the filing of Form 4 for Benitec Biopharma Ltd ADR, pertaining to transactions made up to June 30. Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of company stock. T", "url": "https://ng.investing.com/news/stock-market-news/form-4-benitec-biopharma-ltd-adr-for-30-june-93CH-2580892", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T10:39:27", "published_display": "01 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the BNTC Inflection", "summary": "This article analyzes Benitec Biopharma Inc. (NASDAQ: BNTC) using AI models to provide trading strategies and signal analysis. It highlights mixed sentiment, resistance testing, and an exceptional risk-reward short setup. The analysis includes position, momentum breakout, and ris", "url": "https://news.stocktradersdaily.com/news_release/134/Responsive_Playbooks_and_the_BNTC_Inflection_063026082201_1782865322.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T20:22:00", "published_display": "30 Jun 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (NASDAQ: BNTC) director gifts 51,813 shares to donor-advised fund", "summary": "Benitec Biopharma director J. Kevin Buchi reported a charitable stock gift of 51,813 shares to a donor-advised fund on June 29, 2026. This transaction was a non-market disposition at no stated price, intended for philanthropic purposes, and is not an indication of Buchi's view on", "url": "https://www.stocktitan.net/sec-filings/BNTC/form-4-benitec-biopharma-inc-insider-trading-activity-13f04a0ab310.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:21:46", "published_display": "30 Jun 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 2000 Value Benchmark", "summary": "Benitec Biopharma Inc. (NasdaqCM: BNTC) has been added to the Russell 2000 Value Benchmark. The company, a clinical-stage biotechnology firm, specializes in genetic medicines and is advancing a novel \"Silence and Replace\" gene therapy platform. This addition highlights its recogn", "url": "https://www.marketscreener.com/news/benitec-biopharma-inc-nasdaqcm-bntc-added-to-russell-2000-value-benchmark-ce7f5fdfd88afe2c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:10:05", "published_display": "29 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Value Benchmark Index", "summary": "Benitec Biopharma Inc. (BNTC) has been added to the Russell Microcap Value Benchmark Index. This news follows a previous announcement that the company was also added to the Russell 2000 Value Benchmark Index. The biotechnology company, focused on genetic medicines, recently repor", "url": "https://www.marketscreener.com/news/benitec-biopharma-inc-nasdaqcm-bntc-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd988f727", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:10:05", "published_display": "29 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Small Cap Comp Value Benchmark", "summary": "Benitec Biopharma Inc. (NasdaqCM:BNTC) has been added to the Russell Small Cap Comp Value Benchmark, as reported on June 28, 2026. This indicates the company's inclusion in a significant small-cap index. The article also lists other recent inclusions in various Russell Value Benc", "url": "https://www.marketscreener.com/news/benitec-biopharma-inc-nasdaqcm-bntc-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfd08cf222", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:10:44", "published_display": "28 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQU1o2NW5iVnlNemZVUEloVUl4XzlYVnFRNW9RaVFJM3dYR0RRV0w2T29kcGthVHlic1hndzFTQktGLUpDelV0cmhnbkQ1aDdORlZnMFptbkdqcERyVS1fdWJZSC1KamhyeXM4SlZvaUtibE1XbjNKR3ZuNWpVZ3NsbGRVNlVvWTU4SXhvYkpPUVozeEcyNDhvRkxXaVpCUjFGSDJPTnd6NWwxOWJ6Sll3cERFcUhjUGZhRUlCSlVKaW9OUEQ2S2c?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc Actuals & Estimates (NASDAQ:BNTC)", "summary": "This article provides an overview of Benitec Biopharma Inc. (NASDAQ:BNTC) stock performance, financial data, and analyst estimates. It details the company's current stock price, historical highs and lows, market capitalization, and upcoming earnings report. The piece also include", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTC/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T04:11:22", "published_display": "26 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNTC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Benitec Biopharma Inc. (BNTC) stock, including analyst opinions, historical performance, and key financial metrics. It details the current stock price, volatility, market capitalization, earnings, and revenue, along with the da", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:11:06", "published_display": "25 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc (BNTC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Benitec Biopharma Inc (BNTC), highlighting its current valuation score of 8.43, which ranks 135 out of 389 in the Biotechnology & Medical Research industry. The company's P/E ratio is noted as -13.33. The analysis also states that rel", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bntc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T03:09:26", "published_display": "23 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc (BNTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Benitec Biopharma Inc (BNTC), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. It notes that BNTC is trading between a resistance of 12.55 and support of 10.52, sugge", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bntc/technical", "source_name": "TradingKey", "published_at": "2026-06-18T11:11:29", "published_display": "18 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc (BNTC) Institutional Confidence", "summary": "Benitec Biopharma Inc (BNTC) currently holds an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 96.50%, marking a significant quarter-over-quarter", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bntc/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T11:11:28", "published_display": "18 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc (BNTC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an in-depth look at Benitec Biopharma Inc's (BNTC) shareholder structure, detailing major individual and institutional holdings. It outlines the proportion of shares held by various shareholder types like hedge funds and investment advisors, and tracks insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bntc/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:26", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (Nasdaq:BNTC) - Stock Analysis", "summary": "This article provides a stock analysis for Benitec Biopharma (BNTC), highlighting its position as a clinical-stage biotechnology company focused on genetic medicines, particularly its lead asset BB-301 for OPMD dysphagia. It notes the company's financial risks due to unprofitabil", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntc/benitec-biopharma", "source_name": "Simply Wall Street", "published_at": "2026-06-15T03:39:05", "published_display": "15 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Faces Downgrade Amid Uncertainty", "summary": "Guggenheim downgraded Benitec Biopharma (BNTC) from Buy to Neutral and ceased coverage due to uncertainties surrounding FDA guidance for its pivotal BB-301 study. Despite strong financial strength, the company faces significant challenges in profitability with a low GF Score of 3", "url": "https://www.gurufocus.com/news/8909628/benitec-biopharma-bntc-faces-downgrade-amid-uncertainty?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-10T15:09:23", "published_display": "10 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 25, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (BNTC) That Institutions Follow", "summary": "This article provides a technical analysis of Benitec Biopharma Inc. (NASDAQ: BNTC) based on AI models, indicating weak sentiment across all horizons and suggesting a short bias. It outlines various trading strategies including position trading, momentum breakout, and risk hedgin", "url": "https://news.stocktradersdaily.com/news_release/149/The_Technical_Signals_Behind_BNTC_That_Institutions_Follow_060826060201_1780956121.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-08T18:02:00", "published_display": "08 Jun 2026 18:02", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Slides 2.22% as Shares Approach Critical Support - Earnings Sentiment", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPcTdkb1V1THNBdWU4Uml2OTB1Z3htdjNLaExHVEZCc1lpR3JoVTlpMlM2TEJwa19sVC1VVFFSdjdIWFVKb29DbV9mSlBmN0FyU2NhR240UzlLMjVyNk1IbnNjZmxHcUVIUWFYWElCdm9PZ0JYX3ZHN2puUUp0d1lLMUhfOVZaZWhPLTRuMk1OTlJkbHMzcU5LLTM0cTFQTUwxRVZiTU9jeXN5NlpTZkZSaw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Stays Flat: Technical Trading Range Defines Near-Term Outlook - Volatility Stop", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQTnJiQ1J4MWllR0EwVk1YaVd1UTJXZXAzN01pNnR6M1h1RURtekd3TXNMN3U2TGVrUEZsRFRRZkpKdWFIYl95anEzS0xYRUJuUnNzNXlORDMxNk9hLXVYbHFoQnNOY08tLXNuQkstbmtzXzVJT0ZESmxiaUp1b21mZXIzU3RQSTFVTXZOSDFuTFdNQUNQMjFNNmd3cFNwUU1iSlJDSXVWaDJ3OWZZUFBWOHBQeldTY3FzZlZDS0JmZ3E5cE84?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Stays Flat: Technical Trading Range Defines Near-Term Outlook - Ichimoku TK Cross", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSTM1VkxlZ3QtUERPWERPRzdGbjhMMG5uUFN0dFRqLXVQRnpWcW9JTy0zbmNXUkNFVHdMZkhJNnNGa2dpQzN1YjZpd0o4eE8zcmhVTkxQTmw4YzlpX19pVXdxWmdGWDJocXpUbTJYaW0xWVZ2SWdZU0dJb0U5V1NtS1BGUWYzWkxFMTRtZXZ1d1BrLS1MaXljTUVJcHhnN2NRdmk2SjRycWstcC1JS3lfRWw2VVFXUVZEWUVSaw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Stays Flat: Technical Trading Range Defines Near-Term Outlook - Put Support", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQeVBISlVpWHdaeGI2T1VoMUhFTEw3N0VJZ1NfZHVNdzVOMXNCNFV6UmdTSUVhMmUycW5lUzU4TUM2YlRiYk9uRWRjejNIbURaNFh5UnV6Q0ZoT0lXUXFmWmR2NkhrMjNQRjlITnNUSUhkX3dsUy1xRU9lbVU5ZnNpWGhnY2ZwcHZrTnV2a2JHSl9hcjBXLV9Vei1kR0syR0R2YXFXcGVRVEZQeHN5WnBpY2lDQ1VRRkV5czNxSjF6ak93QQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Benitec Biopharma Inc. (BNTC) Risk Zones", "summary": "This article analyzes Benitec Biopharma Inc. (BNTC) using AI models to provide precise trading strategies. Key findings indicate strong near-term sentiment challenging persistent mid and long-term weakness, with a support test and exceptional risk-reward setup targeting a 17.8% g", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Benitec_Biopharma_Inc._BNTC_Risk_Zones_052826043201_1780000322.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-30T11:08:45", "published_display": "30 May 2026 11:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNTC - Benitec Biopharma Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data and news for Benitec Biopharma Inc. (BNTC). It details the company's stock performance, key financial metrics, recent analyst ratings, and a chronological list of news releases related to its operational updates and clinical tria", "url": "https://finviz.com/stock?t=BNTC", "source_name": "Finviz", "published_at": "2026-05-29T21:10:05", "published_display": "29 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (NASDAQ: BNTC) adds director as CFO exits board role", "summary": "Benitec Biopharma Inc. has appointed David Friedman as a Class III director to its board, effective May 22, 2026, granting him options to purchase 35,000 shares of common stock. Concurrently, CFO and Secretary Megan Boston resigned from the board as part of a governance review, b", "url": "https://www.stocktitan.net/sec-filings/BNTC/8-k-benitec-biopharma-inc-reports-material-event-6163c7716a4b.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:10:53", "published_display": "29 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) director option grant benefits Suvretta-managed funds", "summary": "Benitec Biopharma director David Matthew Friedman was granted 35,000 stock options with an exercise price of $11.45 and an expiration date of May 26, 2036. These options are explicitly held for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd., which ", "url": "https://www.stocktitan.net/sec-filings/BNTC/form-4-benitec-biopharma-inc-insider-trading-activity-08d6002c3062.html", "source_name": "Stock Titan", "published_at": "2026-05-29T02:09:25", "published_display": "29 May 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Announces Board Changes and New Director", "summary": "Benitec Biopharma recently announced board changes, including the appointment of David Friedman as a Class III director and the resignation of Megan Boston, who will continue as CFO. Friedman received options to purchase 35,000 shares of common stock. A recent analyst rating for ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BNTC-Q/pressreleases/2219146/benitec-biopharma-announces-board-changes-and-new-director/", "source_name": "The Globe and Mail", "published_at": "2026-05-29T01:09:50", "published_display": "29 May 2026 01:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) director David Friedman files initial Form 3", "summary": "Benitec Biopharma Inc. director David Matthew Friedman has filed an initial Form 3, which is a regulatory disclosure of his ownership status as a director. This filing serves as a baseline and does not indicate any current shareholdings or recent transactions. The document confir", "url": "https://www.stocktitan.net/sec-filings/BNTC/form-3-benitec-biopharma-inc-initial-statement-of-beneficial-ownershi-1c6b3bf881b3.html", "source_name": "Stock Titan", "published_at": "2026-05-28T19:09:47", "published_display": "28 May 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (NasdaqCM:BNTC) Stock Forecast & Analyst Predictions", "summary": "Benitec Biopharma (BNTC) is a gene therapy company focused on developing therapies for Oculopharyngeal Muscular Dystrophy (OPMD), with its lead asset BB-301 showing promising interim clinical results in Phase 1b/2a trials. Despite positive clinical data and projected revenue grow", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntc/benitec-biopharma/future", "source_name": "Simply Wall Street", "published_at": "2026-05-26T20:40:46", "published_display": "26 May 2026 20:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma\u2019s SWOT analysis: gene therapy stock shows clinical promise", "summary": "Benitec Biopharma (NASDAQ:BNTC) is a clinical-stage biotechnology company making progress with its lead gene therapy candidate, BB-301, for oculopharyngeal muscular dystrophy (OPMD), showing a 100% complete response rate in its Phase 1b/2a clinical study. The company recently sec", "url": "https://m.investing.com/news/swot-analysis/benitec-biopharmas-swot-analysis-gene-therapy-stock-shows-clinical-promise-93CH-4708661?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-25T22:40:40", "published_display": "25 May 2026 22:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNTC News | BENITEC BIOPHARMA INC (NASDAQ:BNTC)", "summary": "This page provides recent news and analysis for BENITEC BIOPHARMA INC (NASDAQ:BNTC), displaying the current stock price and links to detailed company information. It highlights two recent news items: a stock gain due to positive BB-301 data despite an earnings miss, and the relea", "url": "https://www.chartmill.com/stock/quote/BNTC/news", "source_name": "ChartMill", "published_at": "2026-05-19T21:10:09", "published_display": "19 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/benitec-biopharma-releases-third-quarter-120000247.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:00:00+00:00", "published_display": "14 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/benitec-biopharma-announces-oral-presentation-110000396.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T11:00:00+00:00", "published_display": "28 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE1DRkY3S3l4NTZtdi1EcjZMWUpsNThMNEtqSVU3cnZrQ3AyY3pHa2VJLVBMRDVqeWg1MXozbWhLZE01Tjl0bjJlV2JkNmVTWkNXV25HWFhmaEtLRzBzNWZVdW9obXhPYXdPZlJiamF3aGlacGNqR0FGWTFoRGtZcDA?oc=5", "source_name": "Market source", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharm (BNTC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBOdnA0Qzd2c3lZeENFVzZZTU9jNlJCUkszQ0ZDSnd2bDFUTVpGb3N0eHExNFFTTVJzYUlEdVlHdnc4WkVnUUVrYjJtTEhtdEc5OWZ3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:45:45+00:00", "published_display": "25 Apr 2025 02:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9WVDcwcE5CQ0JDdVpINklmR3N0emFUSXZuZ1FENTB4WVR5QUFoNUFBLU1vdVRJSVh5ZHFXOVBfcEdLa054Vm0wMWIyU2UyWU5KYVZxcUlPMFpEbkxpYklFYkVZeUdvZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:46:27+00:00", "published_display": "11 May 2024 14:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "(BNTC) and the Role of Price-Sensitive Allocations", "summary": "This article provides an AI-generated analysis of Benitec Biopharma Inc. (NASDAQ: BNTC), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details specific institutional trading strategies including position, momentum breakout, and risk hedging, alo", "url": "https://news.stocktradersdaily.com/news_release/101/BNTC_and_the_Role_of_Price-Sensitive_Allocations_071126093002_1783819802.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T21:39:45", "published_display": "11 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Benitec Biopharma Inc. \u2013 NASDAQ:BNTC", "summary": "This article provides financial data for Benitec Biopharma Inc. (NASDAQ: BNTC), specifically focusing on its price-to-sales forward metric. The content appears to be a stub or a section from a larger financial data platform like TradingView, showing the header for this specific m", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T04:09:52", "published_display": "03 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNTC - Benitec Biopharma Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Benitec Biopharma Inc (BNTC) as of July 2, with detailed financial metrics, performance indicators, and company statistics. It includes data points such as market capitalization, income, sales, EPS, various ratios, insi", "url": "https://finviz.com/stock?t=BNTC&ta=1&p=d&ty=lf", "source_name": "Finviz", "published_at": "2026-07-02T23:39:40", "published_display": "02 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Benitec Biopharma Ltd ADR For: 30 June By Investing.com", "summary": "This article announces the filing of Form 4 for Benitec Biopharma Ltd ADR, pertaining to transactions made up to June 30. Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of company stock. T", "url": "https://ng.investing.com/news/stock-market-news/form-4-benitec-biopharma-ltd-adr-for-30-june-93CH-2580892", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T10:39:27", "published_display": "01 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the BNTC Inflection", "summary": "This article analyzes Benitec Biopharma Inc. (NASDAQ: BNTC) using AI models to provide trading strategies and signal analysis. It highlights mixed sentiment, resistance testing, and an exceptional risk-reward short setup. The analysis includes position, momentum breakout, and ris", "url": "https://news.stocktradersdaily.com/news_release/134/Responsive_Playbooks_and_the_BNTC_Inflection_063026082201_1782865322.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-30T20:22:00", "published_display": "30 Jun 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (NASDAQ: BNTC) director gifts 51,813 shares to donor-advised fund", "summary": "Benitec Biopharma director J. Kevin Buchi reported a charitable stock gift of 51,813 shares to a donor-advised fund on June 29, 2026. This transaction was a non-market disposition at no stated price, intended for philanthropic purposes, and is not an indication of Buchi's view on", "url": "https://www.stocktitan.net/sec-filings/BNTC/form-4-benitec-biopharma-inc-insider-trading-activity-13f04a0ab310.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:21:46", "published_display": "30 Jun 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 2000 Value Benchmark", "summary": "Benitec Biopharma Inc. (NasdaqCM: BNTC) has been added to the Russell 2000 Value Benchmark. The company, a clinical-stage biotechnology firm, specializes in genetic medicines and is advancing a novel \"Silence and Replace\" gene therapy platform. This addition highlights its recogn", "url": "https://www.marketscreener.com/news/benitec-biopharma-inc-nasdaqcm-bntc-added-to-russell-2000-value-benchmark-ce7f5fdfd88afe2c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:10:05", "published_display": "29 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Value Benchmark Index", "summary": "Benitec Biopharma Inc. (BNTC) has been added to the Russell Microcap Value Benchmark Index. This news follows a previous announcement that the company was also added to the Russell 2000 Value Benchmark Index. The biotechnology company, focused on genetic medicines, recently repor", "url": "https://www.marketscreener.com/news/benitec-biopharma-inc-nasdaqcm-bntc-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd988f727", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:10:05", "published_display": "29 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Small Cap Comp Value Benchmark", "summary": "Benitec Biopharma Inc. (NasdaqCM:BNTC) has been added to the Russell Small Cap Comp Value Benchmark, as reported on June 28, 2026. This indicates the company's inclusion in a significant small-cap index. The article also lists other recent inclusions in various Russell Value Benc", "url": "https://www.marketscreener.com/news/benitec-biopharma-inc-nasdaqcm-bntc-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfd08cf222", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:10:44", "published_display": "28 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQU1o2NW5iVnlNemZVUEloVUl4XzlYVnFRNW9RaVFJM3dYR0RRV0w2T29kcGthVHlic1hndzFTQktGLUpDelV0cmhnbkQ1aDdORlZnMFptbkdqcERyVS1fdWJZSC1KamhyeXM4SlZvaUtibE1XbjNKR3ZuNWpVZ3NsbGRVNlVvWTU4SXhvYkpPUVozeEcyNDhvRkxXaVpCUjFGSDJPTnd6NWwxOWJ6Sll3cERFcUhjUGZhRUlCSlVKaW9OUEQ2S2c?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc Actuals & Estimates (NASDAQ:BNTC)", "summary": "This article provides an overview of Benitec Biopharma Inc. (NASDAQ:BNTC) stock performance, financial data, and analyst estimates. It details the company's current stock price, historical highs and lows, market capitalization, and upcoming earnings report. The piece also include", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTC/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T04:11:22", "published_display": "26 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNTC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Benitec Biopharma Inc. (BNTC) stock, including analyst opinions, historical performance, and key financial metrics. It details the current stock price, volatility, market capitalization, earnings, and revenue, along with the da", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:11:06", "published_display": "25 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc (BNTC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Benitec Biopharma Inc (BNTC), highlighting its current valuation score of 8.43, which ranks 135 out of 389 in the Biotechnology & Medical Research industry. The company's P/E ratio is noted as -13.33. The analysis also states that rel", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bntc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T03:09:26", "published_display": "23 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc (BNTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Benitec Biopharma Inc (BNTC), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. It notes that BNTC is trading between a resistance of 12.55 and support of 10.52, sugge", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bntc/technical", "source_name": "TradingKey", "published_at": "2026-06-18T11:11:29", "published_display": "18 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc (BNTC) Institutional Confidence", "summary": "Benitec Biopharma Inc (BNTC) currently holds an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 96.50%, marking a significant quarter-over-quarter", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bntc/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T11:11:28", "published_display": "18 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Inc (BNTC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an in-depth look at Benitec Biopharma Inc's (BNTC) shareholder structure, detailing major individual and institutional holdings. It outlines the proportion of shares held by various shareholder types like hedge funds and investment advisors, and tracks insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bntc/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:26", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (Nasdaq:BNTC) - Stock Analysis", "summary": "This article provides a stock analysis for Benitec Biopharma (BNTC), highlighting its position as a clinical-stage biotechnology company focused on genetic medicines, particularly its lead asset BB-301 for OPMD dysphagia. It notes the company's financial risks due to unprofitabil", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntc/benitec-biopharma", "source_name": "Simply Wall Street", "published_at": "2026-06-15T03:39:05", "published_display": "15 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Faces Downgrade Amid Uncertainty", "summary": "Guggenheim downgraded Benitec Biopharma (BNTC) from Buy to Neutral and ceased coverage due to uncertainties surrounding FDA guidance for its pivotal BB-301 study. Despite strong financial strength, the company faces significant challenges in profitability with a low GF Score of 3", "url": "https://www.gurufocus.com/news/8909628/benitec-biopharma-bntc-faces-downgrade-amid-uncertainty?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-10T15:09:23", "published_display": "10 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 25, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (BNTC) That Institutions Follow", "summary": "This article provides a technical analysis of Benitec Biopharma Inc. (NASDAQ: BNTC) based on AI models, indicating weak sentiment across all horizons and suggesting a short bias. It outlines various trading strategies including position trading, momentum breakout, and risk hedgin", "url": "https://news.stocktradersdaily.com/news_release/149/The_Technical_Signals_Behind_BNTC_That_Institutions_Follow_060826060201_1780956121.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-08T18:02:00", "published_display": "08 Jun 2026 18:02", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Slides 2.22% as Shares Approach Critical Support - Earnings Sentiment", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPcTdkb1V1THNBdWU4Uml2OTB1Z3htdjNLaExHVEZCc1lpR3JoVTlpMlM2TEJwa19sVC1VVFFSdjdIWFVKb29DbV9mSlBmN0FyU2NhR240UzlLMjVyNk1IbnNjZmxHcUVIUWFYWElCdm9PZ0JYX3ZHN2puUUp0d1lLMUhfOVZaZWhPLTRuMk1OTlJkbHMzcU5LLTM0cTFQTUwxRVZiTU9jeXN5NlpTZkZSaw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Stays Flat: Technical Trading Range Defines Near-Term Outlook - Volatility Stop", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQTnJiQ1J4MWllR0EwVk1YaVd1UTJXZXAzN01pNnR6M1h1RURtekd3TXNMN3U2TGVrUEZsRFRRZkpKdWFIYl95anEzS0xYRUJuUnNzNXlORDMxNk9hLXVYbHFoQnNOY08tLXNuQkstbmtzXzVJT0ZESmxiaUp1b21mZXIzU3RQSTFVTXZOSDFuTFdNQUNQMjFNNmd3cFNwUU1iSlJDSXVWaDJ3OWZZUFBWOHBQeldTY3FzZlZDS0JmZ3E5cE84?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Stays Flat: Technical Trading Range Defines Near-Term Outlook - Ichimoku TK Cross", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSTM1VkxlZ3QtUERPWERPRzdGbjhMMG5uUFN0dFRqLXVQRnpWcW9JTy0zbmNXUkNFVHdMZkhJNnNGa2dpQzN1YjZpd0o4eE8zcmhVTkxQTmw4YzlpX19pVXdxWmdGWDJocXpUbTJYaW0xWVZ2SWdZU0dJb0U5V1NtS1BGUWYzWkxFMTRtZXZ1d1BrLS1MaXljTUVJcHhnN2NRdmk2SjRycWstcC1JS3lfRWw2VVFXUVZEWUVSaw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Stays Flat: Technical Trading Range Defines Near-Term Outlook - Put Support", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQeVBISlVpWHdaeGI2T1VoMUhFTEw3N0VJZ1NfZHVNdzVOMXNCNFV6UmdTSUVhMmUycW5lUzU4TUM2YlRiYk9uRWRjejNIbURaNFh5UnV6Q0ZoT0lXUXFmWmR2NkhrMjNQRjlITnNUSUhkX3dsUy1xRU9lbVU5ZnNpWGhnY2ZwcHZrTnV2a2JHSl9hcjBXLV9Vei1kR0syR0R2YXFXcGVRVEZQeHN5WnBpY2lDQ1VRRkV5czNxSjF6ak93QQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Benitec Biopharma Inc. (BNTC) Risk Zones", "summary": "This article analyzes Benitec Biopharma Inc. (BNTC) using AI models to provide precise trading strategies. Key findings indicate strong near-term sentiment challenging persistent mid and long-term weakness, with a support test and exceptional risk-reward setup targeting a 17.8% g", "url": "https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Benitec_Biopharma_Inc._BNTC_Risk_Zones_052826043201_1780000322.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-30T11:08:45", "published_display": "30 May 2026 11:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNTC - Benitec Biopharma Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data and news for Benitec Biopharma Inc. (BNTC). It details the company's stock performance, key financial metrics, recent analyst ratings, and a chronological list of news releases related to its operational updates and clinical tria", "url": "https://finviz.com/stock?t=BNTC", "source_name": "Finviz", "published_at": "2026-05-29T21:10:05", "published_display": "29 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (NASDAQ: BNTC) adds director as CFO exits board role", "summary": "Benitec Biopharma Inc. has appointed David Friedman as a Class III director to its board, effective May 22, 2026, granting him options to purchase 35,000 shares of common stock. Concurrently, CFO and Secretary Megan Boston resigned from the board as part of a governance review, b", "url": "https://www.stocktitan.net/sec-filings/BNTC/8-k-benitec-biopharma-inc-reports-material-event-6163c7716a4b.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:10:53", "published_display": "29 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) director option grant benefits Suvretta-managed funds", "summary": "Benitec Biopharma director David Matthew Friedman was granted 35,000 stock options with an exercise price of $11.45 and an expiration date of May 26, 2036. These options are explicitly held for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd., which ", "url": "https://www.stocktitan.net/sec-filings/BNTC/form-4-benitec-biopharma-inc-insider-trading-activity-08d6002c3062.html", "source_name": "Stock Titan", "published_at": "2026-05-29T02:09:25", "published_display": "29 May 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Announces Board Changes and New Director", "summary": "Benitec Biopharma recently announced board changes, including the appointment of David Friedman as a Class III director and the resignation of Megan Boston, who will continue as CFO. Friedman received options to purchase 35,000 shares of common stock. A recent analyst rating for ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BNTC-Q/pressreleases/2219146/benitec-biopharma-announces-board-changes-and-new-director/", "source_name": "The Globe and Mail", "published_at": "2026-05-29T01:09:50", "published_display": "29 May 2026 01:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) director David Friedman files initial Form 3", "summary": "Benitec Biopharma Inc. director David Matthew Friedman has filed an initial Form 3, which is a regulatory disclosure of his ownership status as a director. This filing serves as a baseline and does not indicate any current shareholdings or recent transactions. The document confir", "url": "https://www.stocktitan.net/sec-filings/BNTC/form-3-benitec-biopharma-inc-initial-statement-of-beneficial-ownershi-1c6b3bf881b3.html", "source_name": "Stock Titan", "published_at": "2026-05-28T19:09:47", "published_display": "28 May 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (NasdaqCM:BNTC) Stock Forecast & Analyst Predictions", "summary": "Benitec Biopharma (BNTC) is a gene therapy company focused on developing therapies for Oculopharyngeal Muscular Dystrophy (OPMD), with its lead asset BB-301 showing promising interim clinical results in Phase 1b/2a trials. Despite positive clinical data and projected revenue grow", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntc/benitec-biopharma/future", "source_name": "Simply Wall Street", "published_at": "2026-05-26T20:40:46", "published_display": "26 May 2026 20:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma\u2019s SWOT analysis: gene therapy stock shows clinical promise", "summary": "Benitec Biopharma (NASDAQ:BNTC) is a clinical-stage biotechnology company making progress with its lead gene therapy candidate, BB-301, for oculopharyngeal muscular dystrophy (OPMD), showing a 100% complete response rate in its Phase 1b/2a clinical study. The company recently sec", "url": "https://m.investing.com/news/swot-analysis/benitec-biopharmas-swot-analysis-gene-therapy-stock-shows-clinical-promise-93CH-4708661?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-25T22:40:40", "published_display": "25 May 2026 22:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BNTC News | BENITEC BIOPHARMA INC (NASDAQ:BNTC)", "summary": "This page provides recent news and analysis for BENITEC BIOPHARMA INC (NASDAQ:BNTC), displaying the current stock price and links to detailed company information. It highlights two recent news items: a stock gain due to positive BB-301 data despite an earnings miss, and the relea", "url": "https://www.chartmill.com/stock/quote/BNTC/news", "source_name": "ChartMill", "published_at": "2026-05-19T21:10:09", "published_display": "19 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/benitec-biopharma-releases-third-quarter-120000247.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:00:00+00:00", "published_display": "14 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/benitec-biopharma-announces-oral-presentation-110000396.html", "source_name": "GlobeNewswire", "published_at": "2026-04-28T11:00:00+00:00", "published_display": "28 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE1DRkY3S3l4NTZtdi1EcjZMWUpsNThMNEtqSVU3cnZrQ3AyY3pHa2VJLVBMRDVqeWg1MXozbWhLZE01Tjl0bjJlV2JkNmVTWkNXV25HWFhmaEtLRzBzNWZVdW9obXhPYXdPZlJiamF3aGlacGNqR0FGWTFoRGtZcDA?oc=5", "source_name": "Market source", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharm (BNTC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBOdnA0Qzd2c3lZeENFVzZZTU9jNlJCUkszQ0ZDSnd2bDFUTVpGb3N0eHExNFFTTVJzYUlEdVlHdnc4WkVnUUVrYjJtTEhtdEc5OWZ3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:45:45+00:00", "published_display": "25 Apr 2025 02:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benitec Biopharma (BNTC) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9WVDcwcE5CQ0JDdVpINklmR3N0emFUSXZuZ1FENTB4WVR5QUFoNUFBLU1vdVRJSVh5ZHFXOVBfcEdLa054Vm0wMWIyU2UyWU5KYVZxcUlPMFpEbkxpYklFYkVZeUdvZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:46:27+00:00", "published_display": "11 May 2024 14:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 82, "total_relevant": 46, "sentiment_summary": {"positive": 9, "negative": 5, "neutral": 32, "score": 51, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 10.45, "count": 19}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "guidance", "label": "Guidance", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 13.42, "latest_week": "2026-07-10", "one_week_move": 1.5, "four_week_move": 20.0, "twelve_week_move": -4.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.975148, "market_dynamics_buy_signal": false, "relative_strength": -7.95982, "fair_value_gap": 39.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.1918, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.5% over one week, +20.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 5}, {"label": "Stock Traders Daily", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "dars.gov.et", "count": 4}, {"label": "Finviz", "count": 2}, {"label": "www.marketscreener.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 37}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 19}, {"label": "Earnings", "count": 17}, {"label": "Guidance", "count": 6}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "37", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+1.5% over one week, +20.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "(BNTC) and the Role of Price-Sensitive Allocations"}], "updated_at": "2026-07-17T16:23:38.194844+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}